Friday, June 12, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

New opioids called Nitazenes may be 20 times stronger than Fentanyl

Despite the global COVID-19 pandemic, the opioid epidemic persists and seems to be worsening.

In areas throughout the United States, a highly potent new synthetic opioid is starting to show up on the streets and is having devastating effects on its users. A class of opioids called ‘nitazenes’ has recently been found in syringes examined by scientists throughout the country.

Forensic experts have found that the syringes used in some overdoses contain a potent synthetic opioid class — nitazenes — which is up to 20 times more powerful than fentanyl — a drug that is already 50 times more powerful than heroin and 80 to 100 times more potent than morphine.

Source: Healthline

https://www.healthline.com/health-news/new-opioids-called-nitazenes-may-be-20-times-stronger-than-fentanyl

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!